Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Fractyl Health, Inc. Fractyl Health to Participate in Upcoming September Investor Conferences Today 7:00 EDT From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates August 14, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure August 08, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 August 07, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs July 30, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day June 25, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates June 24, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s June 23, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions May 29, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024 May 20, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates May 13, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) May 13, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health to Present at BofA Securities 2024 Health Care Conference May 08, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 May 07, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting April 30, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes April 02, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 01, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs April 01, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity March 12, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity March 12, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials February 20, 2024 From Fractyl Health, Inc. Via GlobeNewswire Tickers GUTS Fractyl Health Announces Pricing of Initial Public Offering February 01, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform January 05, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies Demonstrating Initial Weight Loss and Sustained Weight Maintenance Without Weight Regain Through at Least One Year Post-Revita Procedure December 14, 2023 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Demonstrated That a Single Dose of a GLP-1-Based Pancreatic Gene Therapy Candidate (GLP-1 PGTx) Durably Maintained Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity at WCIRDC 2023 Annual Meeting December 11, 2023 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Expands Landmark Academic-Industry Collaboration to Study Mechanisms Underlying GLP-1-Based Pancreatic Gene Therapy for Type 2 Diabetes and Obesity November 16, 2023 From Fractyl Health, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.